<DOC>
	<DOCNO>NCT03023592</DOCNO>
	<brief_summary>A single-center , self-control , open-label study efficacy safety Iguratimod patient Sjögren 's Syndrome</brief_summary>
	<brief_title>Study Iguratimod Sjögren 's Syndrome</brief_title>
	<detailed_description>In study , patient Sjögren 's Syndrome enrol receive Iguratimod 25 mg twice day 24 week . The difference ESSPRI ( EULAR Sjogren 's Syndrome Patient Reported Index ) score , ESSPRI ( EULAR Sjogren 's Syndrome Patient Reported Index ) score , unstimulated salivary flow rate , Schirmer 's test SF-36 score HAQ score baseline week 24 evaluated determine efficacy Iguratimod patient Sjögren 's Syndrome .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<criteria>A diagnosis Sjogren 's syndrome accord revise AmericanEuropean Consensus Group ( AECG ) criteria Positive dry eye ( ) dry mouth symptom Hyperglobulinemia Complicated systemic autoimmune disease Severe complication Sjogren 's syndrome Glucocorticosteroid therapy , systemic immunosuppressant therapy , biological agent therapy within 3 month prior screen visit Active infection chronic infectious disease A history malignancy Pregnancy breathfeeding Inability comply study protocol reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Sjogren 's Syndrome</keyword>
	<keyword>Iguratimod</keyword>
</DOC>